CAR-T cell therapy has achieved significant successes against hematological malignancies because of two USA FDA-approved CAR-T cells targeting CD-19: KYMRIAH (Tisagenlecleucel) from the Novartis (East Hanover, NJ USA) for treatment of B-cell acute lymphoblastic leukemia (B-ALL) and YESCARTA (Axicabtagene ciloleucel) from the Kite Pharma (Santa Monica, CA USA) for treating diffuse large B-cell lymphoma (DLBCL) [124]. Here, CD19 is linked to diffuse large B-cell lymphoma.